Barinthus Biotherapeutics plc
NasdaqGM:BRNS Rapporto sulle azioni
Cap. di mercato: US$53.2m
Barinthus Biotherapeutics Salute del bilancio
Salute finanziaria criteri di controllo 6/6 Barinthus Biotherapeutics ha un patrimonio netto totale di $159.5M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $188.7M e $29.2M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi n/a Contanti US$106.10m Patrimonio netto US$159.46m Totale passività US$29.23m Totale attività US$188.69m
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer Oct 01
Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth? Aug 31
Barinthus Biotherapeutics plc Plans to Priority on the Development of VTP-300 in Chronic Hepatitis B Virus Infection, or CHB, and VTP-1000 in Celiac Disease Jun 14
Barthus Biotherapeutics plc Announces Updated Data from Two Clinical Trials in People with Chronic Hepat B Jun 08
First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.48 loss in 1Q 2023) May 14
Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective from Beginning of June 2024 May 01
BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections Apr 19
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation Apr 05
New minor risk - Share price stability Apr 05
Consensus revenue estimates increase by 29% Mar 27
Barinthus Biotherapeutics plc, Annual General Meeting, May 10, 2024 Mar 23
New major risk - Revenue size Mar 22
Full year 2023 earnings released: US$1.91 loss per share (vs US$0.14 profit in FY 2022) Mar 22
Insufficient new directors Mar 02
New minor risk - Market cap size Feb 07
Consensus revenue estimates decrease by 20%, EPS upgraded Nov 30
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD Nov 11
Third quarter 2023 earnings released: US$0.36 loss per share (vs US$0.22 profit in 3Q 2022) Nov 11
Vaccitech plc(NasdaqGM:VACC) dropped from NASDAQ Composite Index Nov 08
Price target decreased by 24% to US$9.31 Sep 25
Consensus revenue estimates increase by 26% Sep 22
Consensus revenue estimates decrease by 53%, EPS upgraded Aug 17
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 10
Vaccitech plc Announces Retirement of Margaret Marshall as Chief Medical Officer Jul 28
We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth Jul 07
Vaccitech plc Announces Positive Final Data EASL Congress for Phase 1B/2 HBV002 Study in Adults with Chronic Hepatitis B Jun 22
Vaccitech plc Doses First Patient in Pca001, A Prostate Cancer Phase 1/2 Clinical Trial of Vtp-850 Jun 13
Consensus revenue estimates decrease by 28% May 19
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 13
Consensus revenue estimates increase by 12%, EPS downgraded Mar 31
Price target decreased by 28% to US$14.33 Mar 25
Investor sentiment improves as stock rises 23% Mar 20
Investor sentiment deteriorates as stock falls 17% Feb 24
Vaccitech Appoints Nadège Pelletier as Chief Scientific Officer Jan 31
Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality Nov 17
Consensus forecasts updated Nov 17
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 13
Consensus forecasts updated Nov 12
Vaccitech plc Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B Nov 08
Vaccitech plc Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients Nov 01
Vaccitech plc Announces Publication of Research in Preclinical Animal Models Demonstrating the Potential of Vaccitech’s SNAPvax Oct 28
Vaccitech plc Promotes Gemma Brown as Chief Financial Officer Sep 21
Vaccitech promotes Gemma Brown to CFO Sep 20
Consensus revenue estimates increase by 61% Aug 16
Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts Aug 15
Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next Aug 13
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 11
Price target decreased to US$19.50 Aug 11
Vaccitech GAAP EPS of $0.41, revenue of $17.06M Aug 09
Vaccitech plc Announces an Update to the Interim Analysis of Safety and Efficacy Data from the HBV002 Study Jun 23
Arbutus Biopharma Corporation and Vaccitech plc Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus Jun 07
Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51% May 19
Consensus revenue estimates increase by 51% May 18
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 13
Vaccitech plc, Annual General Meeting, Jun 15, 2022 May 03
Less than half of directors are independent Apr 27
Consensus forecasts updated Apr 08
Vaccitech: Aiming For A Cure In Chronic Hepatitis B Apr 03
Less than half of directors are independent Jan 21
Consensus forecasts updated Jan 20
Consensus forecasts updated Jan 20
Vaccitech plc Announces First Patient Dose in Phase I/Iia Trial of Lung Cancer Immunotherapy Vaccine Jan 18
Vaccitech plc (NasdaqGM:VACC) acquired Avidea Technologies for $40 million. Dec 15
Third quarter 2021 earnings released: US$0.13 loss per share Nov 15
Vaccitech: The Next Big Vaccine Trade Jun 27
Vaccitech EPS misses by $0.69, beats on revenue Jun 14
Vaccitech plc has completed an IPO in the amount of $110.5 million. May 01
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $134.7M ) di BRNS superano le sue passività a breve termine ( $15.1M ).
Passività a lungo termine: Le attività a breve termine di BRNS ( $134.7M ) superano le sue passività a lungo termine ( $14.2M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: BRNS è esente da debiti.
Riduzione del debito: BRNS non aveva debiti 5 anni fa.
Analisi della pista di contanti Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: BRNS ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero .
Previsione Cash Runway: BRNS ha una liquidità sufficiente per 1.3 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 29.2 % ogni anno.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
